nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

19.10.2022 | Research

Efficacy of neoadjuvant immunotherapy in advanced colorectal cancer: a meta-analysis of cross-sectional studies

verfasst von: Yuegang Li, Chi Xue, Ziming Gao, Kai Li, Huimian Xu, Zhi Zhu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Although neoadjuvant immunotherapy is being widely studied, there is no consensus on its efficacy in microsatellite-stable (MSS) or mismatch repair proficient (pMMR) colorectal cancer (CRC). This meta-analysis aimed to evaluate studies on neoadjuvant immunotherapy for advanced CRC to assess its efficacy and provide new clinical guidelines.

Methods

We searched literature databases to identify studies that assessed the efficacy of neoadjuvant immunotherapy in advanced CRC. The outcomes evaluated were pathological complete response (pCR), major pathological response (MPR), R0 resection, and anal preservation rates. Heterogeneity among the included studies was assessed by sensitivity analysis, and publication bias was evaluated using Begg and Egger tests.

Results

Eleven articles were included in the analysis. The pCR, MPR, R0 resection, and anal preservation rates reported in these studies were 39 and 49, 97, and 76%, respectively. The MSI-H and MSS groups had pooled pCR rates of 70 and 24%, respectively. The pCR rates for the induction, consolidation, and concurrent immuno-chemoradiotherapy (CRT) subgroups were 43, 33, and 27%, respectively, and those for the single and double immunotherapy subgroups were 34 and 40%, respectively.

Conclusion

Neoadjuvant immunotherapy combined with CRT is effective in treating MSI-H/dMMR advanced CRC. It could also be a new first-line therapeutic option for MSS/pMMR advanced CRC.

Avallone A, De Stefano A, Pace U et al (2020) 491P neoadjuvant nivolumab in early stage colorectal cancer. Ann Oncol 31:S449. https://doi.org/10.1016/j.annonc.2020.08.602CrossRef

Carrasco J, Schröder D, Sinapi I et al (2021) 397P R-IMMUNE interim analysis: a phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer. Ann Oncol 32:S537. https://doi.org/10.1016/j.annonc.2021.08.919CrossRef

Chalabi M, Fanchi L, Dijkstra K et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26(4):566–576. https://doi.org/10.1038/s41591-020-0805-8CrossRefPubMed

Deng Y, Chi P, Lan P et al (2020) Neoadjuvant modified folfox6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol : off J Am Soc Clin Oncol 37(34):3223–3233. https://doi.org/10.1200/jco.18.02309CrossRef

Diaz LA, Shiu K-K, Kim T-W et al (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23(5):659–670. https://doi.org/10.1016/s1470-2045(22)00197-8CrossRefPubMedPubMedCentral

Hanna C, O’Cathail S, Graham J et al (2020) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol 16(1):163. https://doi.org/10.1186/s13014-021-01888-1CrossRef

Hu H, Kang L, Zhang J et al (2022) Neoadjuvant PD-1 blockade with toripalimab, with or with-out celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally ad-vanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, ran-domised, phase 2 trial. Lancet Gastroenterol Hepatols 7(1):38–48. https://doi.org/10.1016/s2468-1253(21)00348-4CrossRef

Jiao S, Subudhi SK, Aparicio A et al (2019) Differences in tumor microenvironment dictate t helper lineage polarization and response to immune checkpoint therapy. Cell 179(5):1177–1190. https://doi.org/10.1016/j.cell.2019.10.029 (PubMed PMID: 31730856)CrossRefPubMed

Li YJ, Zhang L, Dong QS (2021) Short-term outcome of programmed cell death proteinl (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors. Chin J Gastrointest Surg 24(11):998–1007

Lin Z, Cai M, Zhang P (2022) Correction: phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-003554corr1CrossRefPubMedPubMedCentral

Liu D, Li D, He W et al (2020) PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology 9(1):1711650. https://doi.org/10.1080/2162402x.2020.1711650 (PubMed PMID: 32042474)CrossRefPubMedPubMedCentral

Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1/PD-L1 inhibitors in metastatic dmmr/msi-h colorectal cancer. Front Oncol 9:396. https://doi.org/10.3389/fonc.2019.00396CrossRefPubMedPubMedCentral

Rahma O, Yothers G, Hong T et al (2021) Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol 7(8):1225–1230. https://doi.org/10.1001/jamaoncol.2021.1683CrossRefPubMed

Salvatore L, Bensi M, Corallo S et al (2021) Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC) The AVANA study. J Clin Oncol 39(15–suppl):3511CrossRef

Tamberi S, Grassi E, Corbelli J et al (2021) A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rect-al cancer: PANDORA study first-stage. J Clin Oncol 39(15–suppl):3607. https://doi.org/10.1200/JCO.2021.39.15_suppl.3607CrossRef

Tao S, Tao K, Cai X (2020) Necroptosis-associated lncrna prognostic model and clustering analysis: prognosis prediction and tumor-infiltrating lymphocytes in breast cancer. J Oncol 2022:7099930. https://doi.org/10.1155/2022/7099930CrossRef

Theelen W, Peulen H, Lalezari F et al (2020) Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5(9):1276–1282. https://doi.org/10.1001/jamaoncol.2019.1478CrossRef

Versluis JM, Long GV, Blank CU (2020) Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 26(4):475–484. https://doi.org/10.1038/s41591-020-0829-0CrossRefPubMed

Yuki S, Bando H, Tsukada Y et al (2020) SO-37 short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiothera-py in patients with microsatellite stability and microsatellite instability-high, locally adv-anced rectal cancer (EPOC 1504). Ann Oncol 31:S230–S231. https://doi.org/10.1016/j.annonc.2020.04.052CrossRef

Titel: Efficacy of neoadjuvant immunotherapy in advanced colorectal cancer: a meta-analysis of cross-sectional studies
verfasst von: Yuegang Li
Chi Xue
Ziming Gao
Kai Li
Huimian Xu
Zhi Zhu
Publikationsdatum: 19.10.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04402-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Efficacy of neoadjuvant immunotherapy in advanced colorectal cancer: a meta-analysis of cross-sectional studies

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Brown fat activation demonstrated on FDG PET/CT predicts survival outcome

Effects of gross tumor volume and radiation dose on survival and locoregional recurrence in early-stage extranodal NK/T-cell lymphoma treated with intensity-modulated radiation therapy

Survival influence of gender on 42,345 patients with gastric cardia adenocarcinoma

Secretome analysis reveals reduced expression of COL4A2 in hypoxic cancer-associated fibroblasts with a tumor-promoting function in gastric cancer

Comprehensive analysis of cuproptosis-related genes in prognosis, tumor microenvironment infiltration, and immunotherapy response in gastric cancer

Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie